4D Lifetec develops the 4D Lifetest™, a non-invasive immuno-oncological blood test that utilizes proprietary biomarkers to detect lung cancer at its earliest stages, enhancing the accuracy of early diagnosis. This technology addresses the critical need for timely cancer detection, enabling proactive treatment options and improving patient outcomes.
Funding
$25.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for lung cancer detection often involve invasive procedures or late-stage diagnosis, leading to reduced treatment options and poorer patient outcomes. There is a need for non-invasive, early-stage detection methods to improve survival rates and quality of life for individuals at risk.
Solution
4D Lifetec has developed the 4D Lifetest™ Lung Dx, a non-invasive, immuno-oncological blood test designed for the early detection of lung cancer. The test utilizes a proprietary biomarker, DDS, combined with sophisticated artificial intelligence (AI) to analyze immunological high-throughput blood assays. This approach enables the detection of lung cancer at its earliest stages (I and II), facilitating timely intervention and more effective treatment paths. The 4D Lifetest™ aims to reduce the burden of traditional diagnostic cycles and provide an extra layer of certainty in cancer diagnostics.
Target Audience
The primary target audience includes individuals at risk of lung cancer, healthcare providers seeking early detection methods, and diagnostic labs aiming to improve cancer detection accuracy.
Features
- Non-invasive blood test for early lung cancer detection.
- Utilizes a proprietary DDS biomarker.
- Employs sophisticated AI to enhance immunological high-throughput blood assays.
- Detects lung cancer at stages I and II.
- Complements standard cancer diagnostics.
- Aims to reduce burdensome diagnostic cycles for patients.